ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly capital expenditures (additions to property and equipment, $M) ($M)
Form 10-Q / 10-K Consolidated Statements of Cash Flows & Segment Note
Latest, Q2 2026
2,933
Period ended Jun 30, 2026
Change on a year earlier
+72.8%
1,697 in Q2 2025
History
27 quarters
Since Q1 2019
Sources
19
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Capital expenditures (additions to property and equipment, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2,933 | +72.8% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,326 | +54.0% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,547 | +70.2% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,087 | +54.5% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,697 | +38.6% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,510 | +53.1% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,496 | +39.7% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,351 | +39.2% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,225 | +65.9% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 986 | +47.5% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,071 | +113.9% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2023 | Sep 30, 2023 | 970 | +57.2% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 738 | +99.0% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 669 | +83.0% | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2022 | Dec 31, 2022 | 501 | – | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 617 | +83.3% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 371 | -2.7% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 365 | +21.7% | Form 10-Q (filed 2023-04-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 337 | -14.3% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2021 | Jun 30, 2021 | 381 | +35.3% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 300 | +16.3% | Form 10-Q (filed 2021-04-30) ↗ |
| Q3 2020 | Sep 30, 2020 | 393 | +49.2% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2020 | Jun 30, 2020 | 282 | +17.3% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 258 | +26.8% | Form 10-Q (filed 2020-05-01) ↗ |
| Q3 2019 | Sep 30, 2019 | 263 | – | Form 10-Q (filed 2020-07-31) ↗ |
| Q2 2019 | Jun 30, 2019 | 240 | – | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 204 | – | Form 10-Q (filed 2020-05-01) ↗ |
Cite this data
StockData. (2026). Eli Lilly Capital expenditures (additions to property and equipment, $M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/capex_additions
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.